Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Clinical Trials
5
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2011
Active, not recruiting
1
20.0%
Completed
4
80.0%
No approval data available
- Outlook Therapeutics faces a pivotal FDA decision by December 31, 2025, for ONS-5010/LYTENAVA, which could become the first FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration. - The company's stock has demonstrated notable strength with an 18% climb over two weeks and three consecutive sessions of gains, reflecting investor anticipation ahead of the regulatory milestone. - LYTENAVA has already received approval in Europe and launched commercially in Germany and the UK, providing validation for the therapy's potential in the global ophthalmology market. - The FDA classified the resubmitted Biologics License Application as a complete Class 1 response, triggering a standard 60-day review period with the PDUFA target date set for year-end.
- Outlook Therapeutics' stock surged 11.97% in pre-market trading on August 18, 2025, as investors anticipate the FDA's decision on ONS-5010 (LYTENAVA) scheduled for August 27, 2025. - The investigational ophthalmic formulation of bevacizumab represents the company's second attempt at FDA approval after initial rejection in August 2023 due to chemistry, manufacturing, and controls issues. - ONS-5010 has already received European approval in May 2024 for wet age-related macular degeneration treatment and would receive 12 years of regulatory exclusivity if approved in the United States. - The company resubmitted its Biologics License Application in February 2025, addressing FDA concerns from the Complete Response Letter issued after the initial rejection.
- A new quarterly report identifies 18 significant biopharma catalyst events expected in Q3 2025, including FDA approval decisions for multiple companies across diverse therapeutic areas. - Key regulatory milestones include potential approvals for Ascendis Pharma's Skytrofa for adult growth hormone deficiency, PTC Therapeutics' sepiapterin for phenylketonuria, and Lenz Therapeutics' presbyopia treatment LNZ100. - The report, based on key opinion leader interviews, also covers ongoing clinical trials for Eli Lilly's orforglipron for obesity and aTyr Pharma's efzofitimod for pulmonary sarcoidosis. - Industry experts will assess the commercial potential of these treatments and their impact on existing therapeutic landscapes across multiple disease areas.
- Outlook Therapeutics awaits FDA decision by August 27, 2025, for LYTENAVA (bevacizumab-vikg), which would be the first FDA-approved ophthalmic formulation of bevacizumab in the U.S. with 12 years of regulatory exclusivity. - The company has already secured regulatory approval in the European Union and UK, with successful commercial launches in Germany and UK, including endorsements from NICE and Scottish Medicines Consortium. - LYTENAVA targets the $4 billion+ anti-VEGF market for wet AMD, potentially capturing 20-30% market share by replacing 2.7 million annual off-label bevacizumab injections in the U.S. - New CEO Bob Jahr brings 20 years of commercial expertise to navigate the critical commercialization phase, though the company faces financial challenges with $8.9 million in cash reserves as of June 2025.
- Outlook Therapeutics has commercially launched LYTENAVA™ (bevacizumab gamma) in Germany and the UK, marking the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment in Europe. - The launch addresses a significant market need, with approximately 2.8 million injections of repackaged off-label bevacizumab administered annually in Europe for retinal diseases. - LYTENAVA™ has potential to mitigate certain risks associated with current off-label use of repackaged bevacizumab, while the company plans additional European launches throughout 2025 and 2026. - The company has partnered with Cencora to support global commercial distribution and market access, with a BLA resubmitted to the FDA for potential U.S. approval.
- Guggenheim maintains Buy rating on Outlook Therapeutics while adjusting price target from $12 to $10 following fiscal Q1 earnings report. - Company confirms timeline for ONS-5010 Biologics License Application (BLA) resubmission within calendar Q1, marking a crucial regulatory milestone. - FDA's upcoming review will focus on evaluating ONS-5010's complete clinical package to determine adequacy of controlled studies.
- Outlook Therapeutics' ONS-5010 demonstrated non-inferiority to ranibizumab (Lucentis) at week 12 in the NORSE EIGHT trial for wet AMD. - The company plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025 based on the trial results. - ONS-5010/LYTENAVA has already been granted marketing authorization in the EU and UK, with a commercial launch planned for H1 2025. - The NORSE EIGHT trial showed a mean 5.5 letter improvement in BCVA in the ONS-5010 arm, compared to a 6.5 letter improvement in the ranibizumab arm.
- LYTENAVA (bevacizumab gamma) has been recommended by NICE for treating wet AMD, marking the first positive reimbursement decision worldwide for this ophthalmic formulation. - This decision allows LYTENAVA to be available on the NHS and for Independent Sector Providers, offering a cost-effective anti-VEGF treatment option for approximately 40,000 new wet AMD patients each year in the UK. - Outlook Therapeutics anticipates launching LYTENAVA in the UK in the first half of 2025 and is progressing with pricing and reimbursement processes in EU countries for subsequent launches. - LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK, holding an initial 10 years of market exclusivity.
- Russell Trenary has stepped down as President and CEO of Outlook Therapeutics, effective immediately, after the company achieved EU and UK regulatory approval for LYTENAVA™. - Lawrence Kenyon, the current Executive Vice President and CFO, has been appointed as the Interim CEO to guide the company through this transitional period. - Outlook Therapeutics remains on track to resubmit the BLA for ONS-5010 in Q1 2025 and launch LYTENAVA™ in Europe during the first half of 2025. - The company has initiated a search for a permanent CEO to lead Outlook Therapeutics in its future endeavors and strategic goals.
- Outlook Therapeutics' ONS-5010 failed to meet the noninferiority endpoint in a Phase III wet AMD trial, impacting company shares but BLA resubmission is still planned for early 2025. - The EMA revoked conditional marketing approval for Advanz Pharma's Ocaliva for primary biliary cholangitis (PBC) after a legal challenge failed. - Arovella Therapeutics is advancing ALA-101, a CAR-19-iNKT cell therapy, towards clinical trials for blood cancers and solid tumors, showing enhanced efficacy in preclinical studies.
